Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Cappa M, Setzu S, Bernardini S, Carta D, Federici G, Grossi A, Loche S

Journal of endocrinological investigation1 Nov 1995Cited by 7 (Europe PMC)

PMID8787952DOI10.1007/bf03349808PepBankPUB-08787952

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In normal men given saline, hexarelin raised serum GH by a mean incremental 47.5 micrograms/l.
In plain wordsIn healthy men, hexarelin raised growth hormone in the blood by a mean of 47.5 micrograms/l.
Peptide
Hexarelin
Outcome
IncreaseIncremental serum GH after hexarelin with saline pretreatment
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 micrograms/kg · intravenous · single doseAs given in this study (human).
Measurements
Mean incremental GH change
47.5 micrograms/l
saline + Hex
Source sentences
Summary
Mean incremental change of serum GH from value at time 0 was 47.5 +/- 5.5 and 41.5 +/- 4.1 micrograms/l after saline + Hex and GH + Hex, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine whether the short-term administration of GH inhibits the Hex-induced GH release, we measured the GH response to Hex (2 micrograms/kg iv) in five normal adult males (age 26-32 yr) three h after an iv bolus of rhGH (2 IU) or saline.
Report a problemFND-0878795201
02HumanNon-randomized trialEfficacy outcome
In normal men given saline, the mean incremental GH area under the curve after hexarelin was 3216 micrograms.min.l.
In plain wordsIn healthy men, hexarelin raised growth hormone over time, with a mean incremental area under the curve of 3216.
Peptide
Hexarelin
Outcome
IncreaseGH area under the curve after hexarelin with saline pretreatment
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 micrograms/kg · intravenous · single doseAs given in this study (human).
Measurements
Mean incremental AUC
3216 micrograms.min.1
saline + Hex
Source sentences
Summary
Mean incremental area under the curve over baseline was 3216 +/- 586 and 3735 +/- 506 micrograms.min.1 after saline + Hex and GH + Hex, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine whether the short-term administration of GH inhibits the Hex-induced GH release, we measured the GH response to Hex (2 micrograms/kg iv) in five normal adult males (age 26-32 yr) three h after an iv bolus of rhGH (2 IU) or saline.
Report a problemFND-0878795202

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

03HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In normal men, pretreatment with exogenous GH did not inhibit the GH response to hexarelin (mean incremental 41.5 versus 47.5 micrograms/l).
In plain wordsIn healthy men, a dose of growth hormone given three hours earlier did not reduce the growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
No significant changeIncremental GH after hexarelin following exogenous GH versus saline
Study
n = 5
Comparator
Saline pretreatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean incremental GH change
41.5 micrograms/l
GH + Hex
Mean incremental GH change
47.5 micrograms/l
saline + Hex
Source sentences
Summary
Mean incremental change of serum GH from value at time 0 was 47.5 +/- 5.5 and 41.5 +/- 4.1 micrograms/l after saline + Hex and GH + Hex, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine whether the short-term administration of GH inhibits the Hex-induced GH release, we measured the GH response to Hex (2 micrograms/kg iv) in five normal adult males (age 26-32 yr) three h after an iv bolus of rhGH (2 IU) or saline.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0878795203
04HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In normal men, pretreatment with exogenous GH did not reduce the incremental GH area under the curve after hexarelin (3735 versus 3216).
In plain wordsIn healthy men, earlier growth hormone did not reduce the total growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
No significant changeGH area under the curve after hexarelin following exogenous GH versus saline
Study
n = 5
Comparator
Saline pretreatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean incremental AUC
3735 micrograms.min.1
GH + Hex
Mean incremental AUC
3216 micrograms.min.1
saline + Hex
Source sentences
Summary
Mean incremental area under the curve over baseline was 3216 +/- 586 and 3735 +/- 506 micrograms.min.1 after saline + Hex and GH + Hex, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine whether the short-term administration of GH inhibits the Hex-induced GH release, we measured the GH response to Hex (2 micrograms/kg iv) in five normal adult males (age 26-32 yr) three h after an iv bolus of rhGH (2 IU) or saline.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0878795204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 2
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.